Maze Therapeutics appoints Hervé Hoppenot as board chairman

SOUTH SAN FRANCISCO - Maze Therapeutics, Inc. (Nasdaq:MAZE), a clinical-stage biotech company with a strong balance sheet holding more cash than debt according to InvestingPro data, has appointed Hervé Hoppenot as Chairman of its Board of Directors, replacing Charles Homcy, M.D., who will remain on the board, according to a company press release issued Monday.

Hoppenot brings over 30 years of experience in therapeutic development and commercial leadership. He previously served as Chief Executive Officer of Incyte Corporation from 2014 to 2025 and as Chairman from 2015 to 2025. During his tenure at Incyte, he helped transform the company from a single-product business into a diversified biotechnology company, growing revenue from $350 million to more than $4 billion.

Prior to Incyte, Hoppenot held senior positions at Novartis, including President of Novartis Oncology and Chief Commercial Officer. He currently serves on the boards of Incyte, Laboratoires Pierre Fabre, N-Power Medicine, and Bicycle Therapeutics.

Maze Therapeutics, a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, is advancing several clinical programs. The company’s pipeline includes MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 trials for potential treatment of phenylketonuria and chronic kidney disease. While the company maintains a robust current ratio of 10.39, InvestingPro analysis indicates the company is quickly burning through cash, a common characteristic of clinical-stage biotechs.

The company recently completed a $150 million private placement and is preparing for several clinical milestones in 2026, including initiating Phase 2 trials for MZE782 and obtaining initial topline Phase 2 data for MZE829.

Homcy, a co-founder of Maze, will continue to serve as a board member and on the company’s R&D Committee.

In other recent news, Bicycle Therapeutics has been in the spotlight following its second-quarter 2025 earnings report. RBC Capital responded to the earnings by raising its price target for the company from $25 to $27, maintaining an Outperform rating. Meanwhile, Citizens JMP took a different stance, lowering its price target to $10 from $22, but also kept a Market Outperform rating. Both firms based their evaluations on the company’s financial results and corporate milestones. In a separate development, Bicycle Therapeutics announced the appointment of Roger Dansey, M.D., and Hervé Hoppenot to its Board of Directors. These appointments bring significant oncology expertise to the company, with Dansey having a notable history of contributing to the development of cancer therapies at major pharmaceutical firms. These recent developments highlight the ongoing strategic and financial adjustments at Bicycle Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.